| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-12- | 831906 | 舜宇精工 | 14329241.0 | 38308.93 | 当日收盘价涨幅达到29.98% | | 10 | | | | | | | | 835174 | 五新隧装 | 508868 | 1804.95 | 当日收盘价涨幅达到29.97% | | 10 | | | | | | | | 836422 | 润普食品 | 15164302.0 | 25332.45 | 当日收盘价涨幅达到29.95% | | 10 | | | | | | | 2024-12- | 870726 | 鸿智科技 | 9082403 | 25303.78 | 当日收盘价涨幅达到25.00% | | 10 | | | | | | | | 870726 | 鸿智科技 | 9082403 | 25303.78 | 当日换手率达到56.24% | | 10 | | | | | | | 2024-12- | 920098 | 科隆新材 | ...

Group 1 - Investment Rating: "Accumulate" (First Coverage) [2] - The company is a leading player in the ODM sector of skincare products, actively integrating 5G smart applications and intelligent equipment [5] - The company has shown steady revenue growth, with a compound annual growth rate (CAGR) of 15.24% in revenue and 14.07% in net profit from 2018 to 2023 [5] Group 2 - The skincare segment accounts for 89.19% of the company's revenue in 2023, with a gross margin of 33.61% [11][25] - The company has established stable partnerships with over 1,000 cosmetic brands, including Unilever and SKINTIFIC [6][70] - The cosmetics OEM industry in China is expected to grow from 434.1 billion to 622.9 billion yuan from 2022 to 2025, with a CAGR of 12.79% [6][36] Group 3 - The company has 134 patents and 13,230 product registrations, showcasing its strong R&D capabilities [6][44] - The company has a diversified product range, including skincare, masks, hair care, and color cosmetics, with a focus on ODM services [21][56] - The company has achieved a net profit forecast of 0.45 billion, 0.61 billion, and 0.79 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.53, 0.71, and 0.93 yuan per share [5][8] Group 4 - The company has a strong focus on innovation and quality control, having received multiple certifications and awards in the cosmetics industry [74][75] - The company has implemented a digital management system to enhance production efficiency and quality control [74] - The company’s revenue from testing services was 2.80 million yuan in 2023, with a gross margin of 26.18% [64][68]

证券代码：837023 证券简称：芭微股份 公告编号：2024-113 1.会议召开时间：2024 年 11 月 22 日 2.会议召开地点：芭薇股份创新中心 8 楼会议室 3.会议召开方式：现场和网络视频会议 4.发出董事会会议通知的时间和方式：2024 年 11 月 12 日以电话方式发出 5.会议主持人：董事长冷群英女士 广东芭薇生物科技股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.议案内容： 为满足公司生产经营资金的需要，公司拟向中国工商银行股份有限公司广 州环城支行申请不超过 3000 万元人民币综合授信；向中国民生银行股份有限公 司广州分行申请不超过 5000 万元人民币综合授信；向广州农村商业银行股份有 限公司从化支行申请不超过 1000 万元人民币综合授信。具体详见公司于同日在 北京证券交易所指定信息披露平台（www.bse.cn）披露的《广东芭薇生物科技股 份有限公司关于公司向银行申请综合授 ...

广东芭薇生物科技股份有限公司 关于公司向银行申请综合授信的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 广东芭薇生物科技股份有限公司（以下简称"公司"）于 2024 年 11 月 22 日召开第四届董事会第三次会议，审议通过了《关于公司向银行申请综合授信的 议案》，具体情况如下： 一、基本情况 为满足公司生产经营资金的需要，公司拟向中国工商银行股份有限公司广州 环城支行申请不超过 3000 万元人民币综合授信；向中国民生银行股份有限公司 广州分行申请不超过 5000 万元人民币综合授信；向广州农村商业银行股份有限 公司从化支行申请不超过 1000 万元人民币综合授信。 证券代码：837023 证券简称：芭薇股份 公告编号：2024-112 因 2023 年年度股东大会审议通过《预计公司 2024 年度向银行申请综合授信 额度的议案》，本次授信额度在股东大会审议通过的综合授信额度内，无需再提 交股东大会审议。 三、必要性及对公司的影响 公司向银行申请授信是公司日常业务发展及生产经营的正常需要，有助 ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-11- | 835368 | 连城数控 | 28.85 | 40000 | 申万宏源证券有限公 | 申万宏源证券有限公 | | 05 | | | | | 司吉林分公司 | 司吉林分公司 | | 2024-11- | | | | | 东方证券股份有限公 | 开源证券股份有限公 | | 05 | 837023 | 芭薇股份 | 11 | 100000 | 司上海虹口区曲阳路 | 司上海永泰路证券营 | | | | | | | 证券营业部 | 业部 | | 2024-11- | | | | | 中信建投证券股份有 | 粤开证券股份有限公 | | 05 | 832522 | 纳科诺尔 | 32.44 | 100000 | 限公司北京东三环中 | 司广东分公司 | | | | | | | 路证券营业部 | | | | | | | | 国泰君安证券股份有 | 粤开证券股份有限公 | | 2024-11- 05 | 83249 ...

证券代码：837023 证券简称：芭薇股份 公告编号：2024-111 广东芭薇生物科技股份有限公司股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 1,600,000 股，占公司总股本 1.86%，可交易 时间为 2024 年 11 月 4 日。 | | 股份性质 | 数量（股） | 百分比 | | --- | --- | --- | --- | | | 无限售条件的股份 | 34,266,410 | 39.94% | | 有限售条件的 | 1、高管股份 | 44,334,271 | 51.67% | | 股份 | 2、个人或基金 | 90,000 | 0.10% | | 3、其他法人 | 2,949,319 | 3.44% | | --- | --- | --- | | 4、限制性股票 | 4,160,000 | 4.85% | | 5、其他 | 0 | 0.00% | | 有限售条件股份合计 | 51,533,590 | 60.06% | | 总股本 ...

| | 公告日期 无 | 2024-10-30 | 异常期间 | | | | | --- | --- | --- | --- | --- | --- | --- | | | 芭薇股份(837023) 连续竞价 | | 成交数量 （股） | 12341445.0 | 成交金额（万 元） | 20149.83 | | | 当日收盘价涨幅达到20%的前5只股票 涉及事项 | | | | | | | 买/卖 | 营业部或交易单元名称 | | | | 买入金额（元） | 卖出金额（元） | | 买1 | 东莞证券股份有限公司南京分公司 | | | | 4980043.03 | 0 | | 买2 | 广发证券股份有限公司广州天河路营业部 | | | | 4053400 | 0 | | 买3 | 中信证券股份有限公司北京万柳证券营业部 | | | | 3481086.96 | 0 | | 买4 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | | | | 3134962.24 | 246509.57 | | 买5 | 国泰君安证券股份有限公司广西南宁民族大道营业部 | | | | 2640929.24 | 0 | ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-10- | 832000 | 安徽凤凰 | 24126536.0 | 40469.66 | 异常期间涨跌幅偏离值累计 | | 30 | | | | | 达到67.61% | | 2024-10- | 870204 | 沪江材料 | 31729667.0 | 67880.87 | 异常期间涨跌幅偏离值累计 | | 30 | | | | | 达到67.55% | | 2024-10- | 873223 | 荣亿精密 | 42594651.0 | 47270.81 | 异常期间涨跌幅偏离值累计 | | 30 | | | | | 达到67.50% | | 2024-10- | 836717 | 瑞星股份 | 28931459.0 | 29537.95 | 异常期间涨跌幅偏离值累计 | | 30 | | | | | 达到47.50% | | 2024-10- | 837212 | 智新电子 | 25924840.0 | 45333.71 | ...

第四届监事会第二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 证券代码：837023 证券简称：芭薇股份 公告编号：2024-109 广东芭薇生物科技股份有限公司 二、议案审议情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 29 日 2.会议召开地点：芭薇股份创新中心 8 楼会议室 3.会议召开方式：现场召开 4.发出监事会会议通知的时间和方式：2024 年 10 月 18 日 以电话方式发出 5.会议主持人：监事会主席陈清云先生 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》等法律法规和《公司章程》的相关规 定，所作决议合法合规。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 （一）审议通过《关于公司 2024 年三季度报告》议案 1.议案内容： 具体内容详见公司于 2024 年 10 月 29 日在北京证券交易所信息披露平 台 （www.bse.cn）上披露的《2024 年三季度报告 ...

Financial Performance - Operating revenue for the first nine months of 2024 reached ¥471,201,911.76, a 49.50% increase year-on-year[4] - Revenue for Q3 2024 was ¥205,066,659.35, representing a 101.09% increase compared to Q3 2023[4] - Net profit attributable to shareholders for Q3 2024 increased by 57.52% to ¥14,311,195.11[4] - The company reported a basic earnings per share of ¥0.34 for the first nine months, down 15.81% from the previous year[4] - Total revenue for the first nine months of 2024 reached ¥471,201,911.76, a significant increase from ¥315,175,735.49 in the same period of 2023, representing a growth of approximately 49.5%[24] - Net profit for the first nine months of 2024 was ¥28,764,558.92, compared to ¥30,329,206.28 in 2023, reflecting a decrease of approximately 5.2%[25] - The net profit for the first nine months of 2024 was ¥28,048,676.41, compared to ¥30,136,952.95 in the same period of 2023, indicating a decrease of about 6.9%[26] - The company's total comprehensive income for the first nine months of 2024 was ¥28,022,688.49, down from ¥30,173,428.13 in the same period of 2023, indicating a decrease of approximately 7.1%[27] Cash Flow - Cash flow from operating activities showed a significant decline of 335.58%, resulting in a net outflow of ¥66,266,923.81[4] - The net cash flow from operating activities was -¥66,266,923.81, a decrease of 336% year-over-year, primarily due to an increase in accounts receivable by ¥87.62 million[9] - The net cash flow from operating activities for the first nine months of 2024 was -48,323,658.98, compared to 28,976,060.03 in the same period of 2023, indicating a significant decline[30] - Cash inflow from operating activities totaled ¥443,007,335.59 for the first nine months of 2024, compared to ¥357,853,571.36 in the same period of 2023, representing an increase of about 23.7%[28] - Cash outflow from operating activities increased to ¥484,666,499.86, compared to ¥323,197,323.59 in the prior year, representing a rise of about 50%[30] - The net cash flow from investing activities improved to ¥47,208,971.79, compared to -28,859,797.06 in the same period last year, showing a positive turnaround[30] - Total cash inflow from financing activities was ¥58,084,000.00, compared to ¥15,000,000.00 in the previous year, marking a substantial increase[30] Assets and Liabilities - Total assets increased by 19.51% to ¥792,538,874.54 compared to the end of last year[4] - Total assets increased to CNY 792.54 million as of September 30, 2024, up from CNY 663.18 million on December 31, 2023, representing a growth of approximately 19.5%[20] - Total liabilities increased to CNY 406.47 million from CNY 332.99 million, reflecting a growth of about 22.0%[20] - Total liabilities rose to ¥315,422,499.12, up from ¥274,676,664.07, which is an increase of approximately 14.8%[23] - Shareholders' equity rose to CNY 386.07 million, up from CNY 330.19 million, indicating an increase of approximately 16.9%[20] - The company's equity increased to ¥370,655,485.39 from ¥315,678,571.20, representing a growth of about 17.4%[23] Accounts Receivable and Inventory - Accounts receivable rose by 149% to ¥146,513,980.31, driven by a significant increase in sales[6] - Inventory increased by 93% to ¥99,576,842.05, reflecting higher raw material and finished goods levels due to revenue growth[7] Borrowings and Financial Position - Short-term borrowings surged by 169% to ¥26,964,890.16, indicating increased working capital needs[7] - Long-term borrowings increased to CNY 130.94 million from CNY 105.24 million, representing a growth of about 24.5%[20] - The company reported a decrease in intangible assets to CNY 33.72 million from CNY 35.12 million, a decline of approximately 4.0%[19] Expenses - Operating costs increased to ¥345,549,791.88, reflecting a 67% rise year-over-year, with an increase of ¥139 million[8] - Sales expenses rose to ¥34,110,431.28, a 51% increase from the previous year, with advertising expenses contributing an additional ¥9.39 million[8] - Research and development expenses for the first nine months of 2024 were ¥20,687,231.09, compared to ¥17,868,752.96 in 2023, an increase of approximately 15.5%[24] - The company's financial expenses decreased to ¥2,375,776.79 in the first nine months of 2024, compared to ¥2,987,635.36 in the same period of 2023, reflecting a reduction of about 20.5%[26] - The company reported a decrease in credit impairment losses to ¥-2,736,978.63 from ¥-309,146.78, indicating improved asset quality[25] Shareholder Information - The total number of ordinary shares at the end of the period was 85,800,000, with 32,666,410 shares being freely tradable[11] - The total shareholding of the top ten shareholders accounts for 72.45%, with a total of 62,157,000 shares held[13] - The company has no pledged or judicially frozen shares among the top ten shareholders[14] Future Outlook - Future outlook includes continued focus on market expansion and potential new product development, although specific figures were not disclosed in the call[24] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[26]